Physician profile
Dima Yeshou
NPI 1124287412
$4,941.61
in general payments reported to CMS, 2019-2025
34 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $354 · 2021: $356 · 2022: $863 · 2023: $633 · 2024: $585 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801 · Gift: $59.40 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.84 |
| Gift | $59.40 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $819.01 | 2019-2025 | Korlym |
| Novo Nordisk INC | $769.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $575.67 | 2019-2025 | Evenity, Repatha, Prolia |
| Medtronic, INC. | $333.68 | 2022-2025 | Minimed 780g |
| Lilly USA, LLC | $278.70 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Alexion Pharmaceuticals, INC. | $258.94 | 2024-2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $233.09 | 2019-2025 | |
| Insulet Corporation | $223.48 | 2023-2025 | Omnipod, Omnipod |
| Astrazeneca Pharmaceuticals LP | $219.79 | 2019-2023 | Farxiga |
| Amneal Pharmaceuticals LLC | $197.46 | 2021-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $179.59 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Abbott Laboratories | $179.22 | 2021-2025 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $73.88 | 2024-2025 | Isturisa, Signifor Lar |
| Mannkind Corporation | $73.41 | 2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.46 | 2021-2023 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $45.39 | 2023-2025 | Licart, Tirosint, Tirosint |
| Pfizer INC. | $44.25 | 2021-2022 | |
| Abbvie INC. | $39.44 | 2020-2024 | |
| Senseonics, Incorporated | $38.00 | 2019 | |
| Merck Sharp & Dohme LLC | $31.97 | 2020-2023 | Steglatro |
| Cequr Corporation | $31.57 | 2021-2023 | Cequr Simplicity |
| Acella Pharmaceuticals, LLC | $29.36 | 2024-2025 | NP Thyroid 60 |
| Amryt Pharma Holdings LTD | $29.00 | 2022-2023 | Mycapssa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.83 | 2022-2023 | Cycloset |
| Azurity Pharmaceuticals, INC. | $20.44 | 2023 | Adthyza |
| Beta Bionics, INC. | $17.46 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $17.34 | 2022 | |
| Vivus LLC | $16.72 | 2022 | |
| Tandem Diabetes Care, INC. | $15.87 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Verity Pharmaceuticals INC. | $14.16 | 2025 | Tlando |
| Zealand Pharma US, INC. | $13.37 | 2022 | |
| Shire North American Group INC | $12.96 | 2019 | |
| Amarin Pharma, INC. | $11.15 | 2020 | |
| Clarus Therapeutics INC. | $7.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dima Yeshou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.